News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProImmune Limited Launches Novel Class-Leading CFSE T Cell Proliferation Assays for Assessing Drug Immunogenicity Risk


12/14/2009 8:30:51 AM

OXFORD, England--(BUSINESS WIRE)--ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES